



KANORIA CHEMICALS & INDUSTRIES LIMITED

Registered Office :
KCI Plaza, 6th Floor
23C, Ashutosh Chowdhury Avenue
Kolkata-700 019
Tel : + 91 - 33 - 4031 - 3200
CIN : L24110WB1960PLC024910
E-mail : calall@kanoriachem.com
Website : www.kanoriachem.com

KC-13/

Date: 26.09.2025

To, The Manager, Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: KANORICHEM	To, The Secretary, BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Script Code: 506525
--	---

Dear Sir,


Sub: AGM Presentation

We are attaching herewith the presentation made to the Shareholders at the 65th Annual General Meeting of the Company today, i.e. 26th September, 2025. The same will also be hosted on the website of the Company.

This is for your information and records.

Thanking you,

Yours sincerely,
For Kanoria Chemicals & Industries Limited


Pratibha Jaiswal
Company Secretary




Encl.: as above



Kanoria Chemicals & Industries Limited

65th Annual General Meeting
September 26, 2025



Disclaimer

Except for historical information and discussions contained herein, statements included in this presentation may constitute “forward looking statements”. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ from those that may be projected by these forward looking statements. Kanoria Chemicals & Industries Limited undertakes no obligation to update forward looking statements to reflect events and circumstances after the date thereof.



KEY HIGHLIGHTS FY' 2024-25



Kanoria Chemicals & Industries Limited



- ❑ Improved efficiencies and realisations
- ❑ Operating Revenue increased by 18%
- ❑ EBITDA increased by 69%
- ❑ Exceptional Item represents non cash impairment loss of investments in Subsidiaries
- ❑ Higher Finance Cost due to increased finance requirement primarily towards capacity expansion of Formaldehyde & Hexamine

	(INR in lakhs)	
	FY'2025	FY'2024
Operating Revenue	67,830	57,686
Other Income	1,425	2,524
EBITDA	5,358	3,169
Finance Cost	1,607	1,154
EBTDA	3,751	2,016
Depreciation	1,997	1,827
EBT & Exceptional Item	1,754	188
Exceptional Item	4,499	
EBT from Cont. Operations	(2,745)	188
Tax	1,143	(57)
Profit from Cont. Operations	(3,888)	246
Profit from Disont. Operations	90	(357)
Net Profit	(3,798)	(111)
OCI	(7)	(7)
TCI	(3,805)	(118)
Earnings per Share (INR)	(8.69)	(0.25)



- ❑ Almost flat revenue
- ❑ Negative EBITDA – decreased realisation; higher development cost allocation due to rapid technological changes

	(INR in lakhs)	
	FY'2025	FY'2024
Operating Revenue	78,240	79,007
Other Income	185	81
EBITDA	(663)	2,771
Finance Cost	1,688	1,451
EBTDA	(2,351)	1,320
Depreciation	3,069	2,923
EBT	(5,420)	(1,603)
Tax	36	2,149
Net Profit/(Loss)	(5,456)	(3,752)





- ❑ Results are not comparable as a result of sharp devaluation of Ethiopian Birr by almost 130% post foreign currency liberalization measures announced in July'24 by Government of Ethiopia
- ❑ The revenue in local currency terms increased by 20%
- ❑ A one time cost towards imports committed prior to liberalisation and received post liberalisation also had an adverse impact

	(INR in lakhs)	
	FY'2025	FY'2024
Operating Revenue	7,601	10,811
Other Income	797	109
EBITDA	128	1,850
Finance Cost	2,049	2,334
EBTDA	(1,921)	(484)
Depreciation	1,194	1,181
EBT	(3,115)	(1,665)
Tax	-	-
Net Profit/(Loss)	(3,115)	(1,665)



Consolidated Profitability

	(INR in lakhs)	
	FY'2025	FY'2024
Operating Revenue	1,53,672	1,47,505
Other Income	921	1,925
EBITDA	4,058	7,154
Finance Cost	4,579	4,302
EBTDA	(521)	2,852
Depreciation	6,260	5,932
EBT & Exceptional Item	(6,781)	(3,079)
Exceptional Item	2,944	
EBT from Cont. Operations	(9,725)	(3,079)
Tax	1,179	2,091
Profit from Cont. Operations	(10,905)	(5,171)
Profit from Disont. Operations	90	(357)
Net Profit	(10,815)	(5,528)
OCI	808	606
TCI	(10,007)	(4,922)
Earnings per Share (INR)	(19.13)	(8.79)

Exceptional Item represents impairment of Goodwill created at the time of acquisition of APAG Holding AG



FUTURE OUTLOOK



- ❑ Favourable business prospects with growing demand from Company's customers segment
- ❑ Launch of new product 'Triacetene' by the end of this fiscal.
- ❑ Undertaking Phenol Formaldehyde Resin expansion at its Ankleshwar unit
- ❑ Programs for development of Penta derivative and reduction of steam cost in the manufacturing process are being actively pursued.
- ❑ Continuing thrust on Cost reduction programme launched last year yielding positive results
- ❑ Continued disposal of non core assets to improve liquidity & profitability





- ❑ With challenges of technology disruption: cheaper Asian alternatives and higher allocation of development cost, APAG decided to rope in a Strategic Investor.
- ❑ India's "Anand Group" decided to join hands and have acquired 63% of APAG's equity for EUR 17.78 mn.
- ❑ KCI's participation in APAG diluted from 55% to ~ 14.3%
- ❑ Anand Group to acquire the diluted shareholding in the FY 2030





- ❑ Ethiopia announced a slew of liberalisation measures relating to foreign currency, capital markets, foreign bank collaboration etc., which were all aimed at over all growth of the country
- ❑ These liberalisations are ensuring better availability of foreign exchange and making the Company's products viable in the export market.
- ❑ Expect improved performance and results in the near future.



THANK YOU

